Aptose Biosciences Stock News

Universal Health (UHS) can bank on balance sheet strength for future acquisitions to grow its business inorganically.

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the unde

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the Piper Sandler 33 rd Annual Healthcare Conference, being held virtually.

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been given a consensus recommendation of Buy by the six analysts that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued ratings on the stock in the last year []

Man Group plc lowered its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 24.0% in the second quarter, Holdings Channel.com reports. The fund owned 147,380 shares of the biotechnology companys stock after selling 46,492 shares during the period. Man Group plcs holdings in Aptose Biosciences were worth $489,000 as of its most recent filing with []

Cantor Fitzgerald restated their overweight rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Wednesday, Zacks.com reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences FY2022 earnings at ($0.52) EPS. A number of other research analysts have also commented on APTO. Zacks Investment Research raised Aptose Biosciences from a []

Cantor Fitzgerald restated their overweight rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Wednesday morning, Zacks.com reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences FY2022 earnings at ($0.52) EPS. Other equities analysts have also recently issued reports about the stock. HC Wainwright boosted their target price on shares of []

Aptose Biosciences (TSE:APS) (NASDAQ:APTO)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Wednesday, Zacks.com reports. Separately, HC Wainwright reiterated a “buy” rating and set a C$14.00 price objective on shares of Aptose Biosciences in a research note on Friday, November 12th. Aptose Biosciences stock opened at […]

Bruton Tyrosine Kinase (BTK) Inhibitors Market Report for Forecast Period 2021-2027: The report presents the prevailing drivers, restraints, opportunities, and current trends in the Bruton Tyrosine Kinase (BTK) Inhibitors industry. The Bruton Tyrosine Kinase (BTK) Inhibitors Market report highlights in-depth

Aptose Biosciences Inc. (NASDAQ:APTO) price closed higher on Friday, November 12, jumping 10.00% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Aptose Biosciences Inc.'s (APTO) CEO William Rice on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underl

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl

These Penny Stocks Have Insiders Excited To Buy Right Now. The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | Penn